Be part of our Research

Gene Editing Scientist

Job Summary:

Censo Biotechnologies Ltd is looking to employ a Gene Editing Scientist to work within our induced pluripotent stem cell (iPSC) services department. The main function of the role will be to perform gene edits in human stem cells in accordance with client specifications.

Based in Midlothian, Censo Biotechnologies Ltd is a leader in the generation, banking and testing of induced pluripotent stem cell (iPSC) lines, their differentiation into many cell types and their use in drug discovery and development. This is an exciting opportunity to join an expanding biotech company in the stem cell field.

Job Description:

We are seeking to recruit a Gene Editing Scientist to assist with our busy iPSC production activities. Reporting to the Head of Pluripotent Sciences, the successful candidate will be responsible for designing gene editing strategies as per client’s specifications, preparing proposals and costings, and for guiding a small team to deliver on the final product within the required timeframe. In addition, the successful candidate will be responsible for staying abreast of recent developments in the gene editing field and disseminating this information to colleagues.

The role will involve:

  • Designing gene editing strategies and liaising with the business development team to convert these into proposals for clients.
  • Carrying out gene edits as per the agreed work plan and timeframe.
  • Preparing reports on project progress and presenting these both internally to colleagues and to clients.
  • Maintaining meticulous records of all laboratory-based work.
  • Preparation and maintenance of Standard Operating Procedures (SOPs).
  • Supervising and providing training as needed for a small gene editing/cell culture team.
  • Staying up to date with recent advances in gene editing technologies, and disseminating this information to team members and the wider company.

Minimum qualifications and experience required:

  • MSc or PhD/DPhil in the biological sciences. Applicant must have extensive relevant laboratory experience.
  • Very experienced in the use of CRISPR/Cas9 gene editing technology, preferably in human stem cells.
  • Experienced in the culture of human embryonic or induced pluripotent stem cells.
  • Experienced in a wide-range of molecular biology techniques.
  • Experience in an industry setting is beneficial, but not essential.
  • A good scientific knowledge of stem cell characterisation and biology is important.
  • Excellent record keeping skills with a good eye for detail.
  • Organisational, planning and time management skills with the ability to plan ahead whilst delivering results to deadline.
  • Previous experience in staff supervision is highly beneficial.

Skills required:

  • Molecular biology techniques should include PCR, qPCR, restriction cloning (including Gibson methodology), transfections, transformations and preferably Western/Southern blot.
  • Experienced in developing cloning strategies for generation of complex constructs.
  • Experience in preparing samples for and analysing Sanger sequencing data.
  • Experience in droplet digital PCR (ddPCR) is highly beneficial, but not required.
  • Experience in flow cytometry and fluorescent microscopy is beneficial, but not required.
  • Successful candidate will be very familiar with DNA cloning software packages (eg. Snapgene, Vector NTI, Serial Cloner etc.) as well as online guide-RNA design tools.
  • Must be very experienced in troubleshooting general molecular biology methods, especially PCR.
  • Excellent project management and interpersonal skills, with the ability to interact effectively with internal and external colleagues and collaborators.
  • Excellent presentation skills and an ability to convey complex scientific concepts and data to others is essential.

As well as being involved in an exciting and expanding company, we are offering a competitive salary and benefits package.

To apply, please send your CV and a covering letter to: enquiries@censobio.com

Closing Date: 05 April 2019